Cargando…
Progress and pitfalls of a year of drug repurposing screens against COVID-19()
Near the end of 2019, a new betacoronavirus started to efficiently transmit between humans, resulting in the current COVID-19 pandemic. Unprecedented worldwide efforts were made to identify and repurpose antiviral therapeutics from collections of approved drugs and known bioactive compounds. Typical...
Autores principales: | Sourimant, Julien, Aggarwal, Megha, Plemper, Richard K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214175/ https://www.ncbi.nlm.nih.gov/pubmed/34218010 http://dx.doi.org/10.1016/j.coviro.2021.06.004 |
Ejemplares similares
-
Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment
por: Taibe, Noha Samir, et al.
Publicado: (2022) -
Organization, Function, and Therapeutic Targeting of the Morbillivirus RNA-Dependent RNA Polymerase Complex
por: Sourimant, Julien, et al.
Publicado: (2016) -
Viral evolution identifies a regulatory interface between paramyxovirus polymerase complex and nucleocapsid that controls replication dynamics
por: Sourimant, Julien, et al.
Publicado: (2020) -
Structural Insight into Paramyxovirus and Pneumovirus Entry Inhibition
por: Aggarwal, Megha, et al.
Publicado: (2020) -
Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity
por: Cox, Robert M., et al.
Publicado: (2021)